Clinical trials: Outpatient Treatment
Rheumatoid Arthritis
A Study to Determine the Number of Participants With Rheumatoid Arthritis (RA) Who Meet the Requirements for Treatment With Anti-Tumor Necrosis Factor α (TNFα) in a General Hospital Setting in Korea
This is an observational study to estimate the proportion of patients diagnosed with RA visiting a medical internist in a general hospital in Korea who are candidates for anti-TNF α therapy.
- Trial name
- NCT01294722
- Where
- South Korea
- Volunteers
- 1,700 people
- Sponsor
- Janssen Korea, Ltd., Korea
Schizophrenia
A Retrospective NIS to Evaluate the Use of Seroquel XR and IR in the Clinical Practice of Outpatients With Schizophrenia
The primary objective of this non-interventional study is to investigate how Seroquel XR and Seroquel IR are used in the clinical practice of outpatients with schizophrenia.
- Trial name
- NCT01212575
- Where
- 13 sites in Denmark
- Volunteers
- 186 people
- Sponsor
- AstraZeneca
Bipolar Disorder
Topiramate Versus Placebo as add-on Treatment in Patients With Bipolar Disorder in the Outpatient Setting
The purpose of this study is to assess the efficacy and safety of adding topiramate as compared to placebo to the medications a patient with bipolar disorder is already taking (lithium or valproate) to see if adding topiramate…
- Trial name
- NCT00237289
- Testing
- topiramate
- Volunteers
- 287 people
- Sponsor
- Ortho-McNeil Neurologics, Inc.
Schizophrenia
A Study to Evaluate Participants Satisfaction, Quality of Life and Effectiveness of Flexible-Dose of Paliperidone Extended Release (ER) in Participants With Schizophrenia, Previously Treated With Risperidone
The purpose of this study is to evaluate effectiveness, tolerability (how well a participant can stand a particular medicine or treatment), and safety of flexible-dose of paliperidone extended release (ER) in participants with…
- Trial name
- NCT01010776
- Testing
- Paliperidone Extended Release (ER)
- Where
- 10 sites in Brazil
- Volunteers
- 223 people
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
Major Depressive Disorder
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)
A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression
- Trial name
- NCT00034983
- Testing
- aprepitant, Comparator: paroxetine HCL
- Volunteers
- 900 people
- Sponsor
- Merck Sharp & Dohme LLC
Major Depressive Disorder
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
This is a double-blind study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) versus placebo in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder (MDD).
- Trial name
- NCT01371734
- Testing
- Desvenlafaxine Succinate Sustained-Release
- Where
- 42 sites in United States, Chile and 1 more
- Volunteers
- 363 people
- Sponsor
- Pfizer
Depressive Disorder, Major, Depression
Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment of Major Depressive Disorder
Evidence exists supporting the ability of genetic variations to influence patient drug response and side effects. Previous studies utilizing an open-label design have shown significant improvement in major depressive disorder…
- Conditions
- Depressive Disorder, Major, Depression, Depressive Disorder
- Trial name
- NCT02466477
- Testing
- GeneSight Psychotropic (GEN), Enhanced-GeneSight Psychotropic (E-GEN), Treatment as Usual (TAU)
- Where
- 14 sites in Canada
- Volunteers
- 542 people
- Sponsor
- Assurex Health Inc.